MedPath

Effect of Kimchi Intake on Body Fat in Overweight Subjects

Not Applicable
Not yet recruiting
Conditions
Obesity
Interventions
Dietary Supplement: Placebo
Dietary Supplement: Kimchi
Registration Number
NCT05898802
Lead Sponsor
World Institute of Kimchi
Brief Summary

Kimchi, a traditional Korean food, is prepared through the fermentation of various ingredients. It has been reported that kimchi contains beneficial nutrients from its raw materials, as well as lactic acid bacteria (LAB) and their byproducts produced during fermentation. LAB play an important role in the fermentation process, during which the dominant LAB species emerge and undergo a transition process. Depending on the species and strain of LAB, it has specific functions such as promoting weight loss, reducing inflammation, and lowering cholesterol levels. In this study, the effects of kimchi produced from traditional recipe or kimchi fermented with lactic acid bacteria, which have anti-obesity effects, on body composition changes and metabolic disease index will be investigated in subjects with a BMI of between 23\~30kg / m2.

Detailed Description

This is a randomized, double-blind, placebo-controlled clinical trial to investigate the anti-obesity effect of kimchi fermented with the addition of specific lactic acid bacteria.

Two different kimchi, one traditional kimchi and one fermented with a lactic acid bacteria having anti-obesity effect, hereafter starter kimchi, are flash freeze dried, powdered and encapsulated. Specifically, subjects with a BMI of between 23\~30kg/m2 take 1,200 mg of traditional kimchi or starter kimchi capsules three times per day before each meal, for a total of 3,600 mg per day. As a control, subjects with a BMI of 23 to 30 kg/m2 take lactose capsules in a similar form and in the same amount. The total study period is 16 weeks of intake of kimchi capsules or placebo capsules, excluding the 2 weeks of preparation period for subject selection. Before and after taking the kimchi capsule or the placebo capsule, the following evaluation criteria of the subject will be measured; DEXA (Dual Energy X-ray Absorptiometry), BMI, Weight, Waist to Hip ratio (WHR), total cholesterol, triglyceride, HDL-C, calculate LDL-C, FFA, HbA1c, glucose, insulin, HOMA-IR, hs-CRP, Adiponectin, Leptin. Also, Changes in gut microbiome composition will be determined by measuring bacterial population levels in stool samples collected before and after taking kimchi capsules or placebo capsules.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
102
Inclusion Criteria
  • Willing to consent to study participation and to comply with study requirements
  • Male and female subjects, 20-65 years of age
  • BMI of 23-30 kg/m2
  • Those who agreed not to consume Kimchi during the clinical study
Exclusion Criteria
  • Patients with crucial cerebrovascular disease (cerebral infarction, cerebral hemorrhage etc.), or heart failure (angina pectoris, myocardial infarction, heart failure, arrhythmia etc.) or malignancy within 6 months
  • Uncontrolled hypertension (Elevated blood pressure (>160/>100))
  • Thyroid function test abnormality
  • Patients with significantly impaired kidney function: serume creatinine levels ≥2 times upper limit of normal
  • Patients with significantly impaired liver function: ALT or AST≥3 times upper limit of normal
  • Irregular or occasional gastrointestinal disorders (heartburn, indigestion, etc.)
  • Having taken drugs with a known influence on weight in the previous 1 month, such as diet pills, anti-depression drugs, beta-blockers, diuretic, contraceptives, corticosteroids, or female hormones
  • Participation in other dietary programmes or services within 3 months
  • Participation in other clinical trials within the past 1 month
  • Alcohol abuse
  • Quitted smoking within 3 months
  • Pregnancy or lactation or planning on becoming pregnant
  • Have a Kimchi allergy
  • Those who are judged unsuitable by the researcher for other reasons
  • Taking probiotics within 2 weeks

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LactosePlacebo3,600mg/day containing lactose placebo capsules to look identical. (3 tablets 3 times per day after meals over the 16-week regimen)
KimchiKimchi3,600mg/day containing 80% Kimchi powder (3 tablets 3 times per day after meals over the 16-week regimen)
Kimchi inoculated Leuconostoc mesenteroidesKimchi3,600mg/day containing 80% Kimchi inoculated Leuconostoc mesenteroides powder (3 tablets 3 times per day after meals over the 16-week regimen)
Primary Outcome Measures
NameTimeMethod
Fat mass change in 16-week8 weeks, 16 weeks

Fat mass is measured by DEXA(Dual Energy X-Ray Absorptiometry)

Secondary Outcome Measures
NameTimeMethod
Changes in body mass index (BMI)8 weeks, 16 weeks
Changes in Body fat ratio (%)8 weeks, 16 weeks

Body fat ratio (%) will be assessed by DEXA

Changes in body weight8 weeks, 16 weeks
Changes in free fatty acids (FFA) concentration8 weeks, 16 weeks
Changes in HOMA-IR value8 weeks, 16 weeks

HOMA -IR is the product of insulin x glucose and describes the level of insulin resistance

Change of Microbiota composite8 weeks, 16 weeks
Changes in waist to hip ratio (WHR)8 weeks, 16 weeks
Changes of serum hs-CRP8 weeks, 16 weeks
Changes in leptin8 weeks, 16 weeks
Changes in Body lean mass (kg)8 weeks, 16 weeks

Body lean mass (kg) will be assessed by DEXA

Changes in serum lipid profile (Total cholesterol, Triglycerides,Low-density lipoprotein,High density lipoprotein)8 weeks, 16 weeks
Changes in adiponection8 weeks, 16 weeks
Changes in HbA1c8 weeks, 16 weeks
Changes in fasting glucose concentration8 weeks, 16 weeks
Changes in insulin resistance8 weeks, 16 weeks
© Copyright 2025. All Rights Reserved by MedPath